Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Rémy Gébleux"'
Autor:
Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic, Ulf Grawunder, Sai Reddy, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a novel HER2-targeting ADC bearing
Externí odkaz:
https://doaj.org/article/fc1ae255093f4779af3f20d721a4f07a
The development of antibody–drug conjugates (ADC), a promising class of anticancer agents, has traditionally relied on the use of antibodies capable of selective internalization in tumor cells. We have recently shown that also noninternalizing anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440c1f095c3628764bef5113749432df
https://doi.org/10.1158/1535-7163.c.6538348
https://doi.org/10.1158/1535-7163.c.6538348
Autor:
Roger R. Beerli, Ulf Grawunder, Fabian I. Wolter, Marie Escher, Tamara Hell, Lorenz Waldmeier, Rémy Gébleux, Nikolas Stefan
Legends to Supplementary Figures S1-S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3d4ad8a074048317878283e93a615a
https://doi.org/10.1158/1535-7163.22509808
https://doi.org/10.1158/1535-7163.22509808
Autor:
Roger R. Beerli, Ulf Grawunder, Fabian I. Wolter, Marie Escher, Tamara Hell, Lorenz Waldmeier, Rémy Gébleux, Nikolas Stefan
In vitro cytotoxicity assays with HER2-positive and -negative cell lines using sortase A-conjugated, anthracycline-based anti-HER2 ADCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d4067105d74433222eecac98b81d9f4
https://doi.org/10.1158/1535-7163.22509802.v1
https://doi.org/10.1158/1535-7163.22509802.v1
Autor:
Roger R. Beerli, Ulf Grawunder, Fabian I. Wolter, Marie Escher, Tamara Hell, Lorenz Waldmeier, Rémy Gébleux, Nikolas Stefan
Antibody–drug conjugates (ADC) are highly potent and specific antitumor drugs, combining the specific targeting of mAbs with the potency of small-molecule toxic payloads. ADCs generated by conventional chemical conjugation yield heterogeneous mixtu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ce4561346675ea9000fdd20167ae48
https://doi.org/10.1158/1535-7163.c.6539398
https://doi.org/10.1158/1535-7163.c.6539398
Supplementary Fig S1 : Amino acid sequences of the constructs used. Supplementary Fig S2 : ESI-MS spectra depicting the SIP(F8)-SS-DM1 and the internal standard used. Supplementary Fig S3 : ESI-MS spectra of conjugated and unconjugated IgG(F8)-SS-DM1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5c3781bd29e08a93267e1a47f1d221
https://doi.org/10.1158/1535-7163.22506286
https://doi.org/10.1158/1535-7163.22506286
Autor:
Roger R. Beerli, Fabian I. Wolter, Ulf Grawunder, Tamara Hell, Lorenz Waldmeier, Rémy Gébleux, Nikolas Stefan, Marie Escher
Publikováno v:
Molecular Cancer Therapeutics. 16:879-892
Antibody–drug conjugates (ADC) are highly potent and specific antitumor drugs, combining the specific targeting of mAbs with the potency of small-molecule toxic payloads. ADCs generated by conventional chemical conjugation yield heterogeneous mixtu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94a87b09d84dd27038f02279b57c8aa2
https://doi.org/10.1158/1535-7163.mct-16-0688
https://doi.org/10.1158/1535-7163.mct-16-0688
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2012
Antibody-drug conjugates (ADCs) are highly potent targeted anticancer therapies. They rely on the linking of a selectively targeting antibody moiety with potent cytotoxic payloads to effect antitumoral activity. In recent years, one focus in the ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51a7e2be02580afc1daf91e8fac29a2c
https://pubmed.ncbi.nlm.nih.gov/31161500
https://pubmed.ncbi.nlm.nih.gov/31161500
Publikováno v:
Methods in Molecular Biology ISBN: 9781493995455
Antibody-drug conjugates (ADCs) are highly potent targeted anticancer therapies. They rely on the linking of a selectively targeting antibody moiety with potent cytotoxic payloads to effect antitumoral activity. In recent years, one focus in the ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5561224555f5caa3fdcbf5e756756bcf
https://doi.org/10.1007/978-1-4939-9546-2_1
https://doi.org/10.1007/978-1-4939-9546-2_1
Autor:
Rémy Gébleux, Giulio Casi
Publikováno v:
Pharmacology & Therapeutics. 167:48-59
Conventional cytotoxic agents used for the pharmacotherapy of cancer do not selectively localize at the tumor site, which may prevent dose escalation to therapeutically active regimens and may lead to undesired side effects and toxicity to normal org
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7520df6a927b685247fb396af4a45ead
https://doi.org/10.1016/j.pharmthera.2016.07.012
https://doi.org/10.1016/j.pharmthera.2016.07.012